Interim Report – January to September 2014

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its Interim Report covering the Third Quarter 2014.

Financial Highlights

• Revenue for the 3rd quarter 2014 SEK 11.5 (22.3) million, and for the nine month period to 33.5 (45.5) million
• Operating result for the period amounted to SEK 0.4 (7.5) million, and for the nine month period to -3.2 (6.8) million
• EBITDA for the period amounted to SEK 0.5 (7.6) million, and for the nine month period to -2.9 (7.0) million
• Net result for the period amounted to SEK 0.1 (7.1) million, and for the nine month period to -4.2 (5.7) million
• Cash flow for the period was SEK -3.4 (2.8) million, and for the nine month period to -7.1 (-0.7) million
• Cash and cash equivalents at the end of the period amounted to SEK 26.0 (20.6) million

Significant events during the  quarter

• No significant events were reported during the quarter

Other significant events during 2014

• The first patient was included in a PET Imaging Study of HER2 Expression in Breast Cancer at Herlev University Hospital
• An Annual General Meeting on May 8 elected Håkan Åström, Jakob Lindberg, Mathias Uhlén and Jonathan Knowles as Directors of the Board
• Investor AB acquired all HealthCap’s shares in Affibody

Significant events after the end of the reporting period

• In October 2014, Sobi decided to place the phase 1 study of SOBI002 on clinical hold as adverse events were observed in the first-in-human study. All subjects that have been dosed with SOBI002 are well. Sobi is now working to understand these adverse events.